MEDP
NasdaqMedpace Holdings, Inc.
Industrials · Services-Commercial Physical & Biological Research
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$1.1B
2021
$1.5B
2022
$1.9B
2023
$2.1B
2024
$2.5B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$2.5B
Net Income$451.1M
Gross Profit—
Oper Income$534.9M
EPS (dil)$15.28
Rev/sh$88.59
FCF/sh$23.88
Book/sh$16.07
Gross M—
Oper M21.1%
Profit M17.8%
FCF M26.9%
ROE98.3%
ROA22.8%
ROIC—
R&D/Rev—
Rev Y/Y20.0%
Rev 3Y CAGR20.1%
EPS Y/Y21.0%
EPS 3Y CAGR28.0%
FCF 3Y CAGR24.8%
Payout—
Div/sh—
Shs Chg Y/Y-7.8%
Current Ratio0.74
Quick Ratio—
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$497.0M
Total Assets$2.0B
Oper CF$713.2M
Capex$31.4M
Free CF$681.9M
Buybacks$917.4M
Equity$459.1M
Liabilities$1.5B
Shs Outstand0.03B
SectorIndustrials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.5B | $1.9B | $2.1B | $2.5B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $198.6M | $278.7M | $336.8M | $446.9M | $534.9M |
| Net Income | $181.8M | $245.4M | $282.8M | $404.4M | $451.1M |
| Diluted EPS | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| Operating Cash Flow | $263.3M | $388.1M | $433.4M | $608.8M | $713.2M |
| Free Cash Flow | $235.1M | $351.2M | $396.7M | $572.3M | $681.9M |
COMMUNITY · $MEDP0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.